Literature DB >> 22257696

Role of the purinergic system in patients with cervical intraepithelial neoplasia and uterine cancer.

Paula Acosta Maldonado1, Victor Camera Pimentel, Luiz Augusto Negrini, Vera Maria Morsch, Maria Rosa Chitolina Schetinger.   

Abstract

INTRODUCTION: Cervical cancer remains the second leading cause of death among women. Intraepithelial neoplasias and uterine invasive cancer are frequently associated with disturbances in coagulation and changes in the concentrations of adenine nucleotides. This work intended to analyze changes in extracellular adenine nucleotide hydrolysis and blood platelet aggregation in patients diagnosed for cervical intraepithelial neoplasia in different stages as well as uterine invasive cancer. PATIENTS AND METHODS: NTPDase, E-NPP, 5'-nucleotidase, total ADA and its isoforms (ADA1 and ADA2), as well as the platelet aggregation from patients with different stages of cervical intraepithelial neoplasia (NICs I, NIC II, NIC III) and uterine invasive cancer were verified.
RESULTS: Neither ATP hydrolysis nor E-NPP activity was changed by the neoplasia stage. On the other hand, ADP and AMP hydrolysis as well as ADA activity were enhanced in NIC I group. AMP hydrolysis was also increased in the cancer group. ADA 1 was the ADA isoform found in platelets from both control and patient groups.
CONCLUSION: Our results showed for the first time that NTPDase, 5'-nucleotidase, E-NPP and ADA are not sensible regarding the grade of neoplasia development, since no significant difference was found between the groups studied. Only ADP hydrolysis and ADA activity showed a significant enhancement in NIC I group related to the other stages possibly as a result of the beginning of the neoplasic transformation. This increase could be reflecting a body's reaction against the probable high adenosine levels. We propose for the first time that the ADA isoform present in platelets is ADA 1.
© 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22257696     DOI: 10.1016/j.biopha.2011.09.007

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  [LC-MS/MS-based screening of new protein biomarkers for cervical precancerous lesions and cervical cancer].

Authors:  Feng Qiu; Fu Chen; Dongdong Liu; Jianhua Xu; Jingling He; Jujiao Xiao; Longbin Cao; Xianzhang Huang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 3.  Inflammatory profile in cervical cancer: influence of purinergic signaling and possible therapeutic targets.

Authors:  Maria Luiza Mukai Franciosi; Thiago Inácio Teixeira do Carmo; Daniela Zanini; Andréia Machado Cardoso
Journal:  Inflamm Res       Date:  2022-04-04       Impact factor: 4.575

Review 4.  Purinergic signaling and tumor microenvironment in cervical Cancer.

Authors:  Marta Schmidt Pfaffenzeller; Maria Luiza Mukai Franciosi; Andréia Machado Cardoso
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

5.  Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions.

Authors:  María de Lourdes Mora-García; Rosario García-Rocha; Omar Morales-Ramírez; Juan José Montesinos; Benny Weiss-Steider; Jorge Hernández-Montes; Luis Roberto Ávila-Ibarra; Christian Azucena Don-López; Marco Antonio Velasco-Velázquez; Vianey Gutiérrez-Serrano; Alberto Monroy-García
Journal:  J Transl Med       Date:  2016-10-26       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.